Q3 2021 BioInvent International AB Earnings Call Transcript
Thank you very much, and welcome, everybody, to our webcast covering our Q3 report. And I would like to go to the second slide, please. Thank you. So I would like to start with a quick summary of the highlights that we summarize also in our Q3 report. I'll just go through this very quickly.
So we were very pleased with our second clinical trial and supply agreement with Merck, this time for BI-1808 in combination with pembrolizumab. And I will come back to that later a little bit more in detail. And I'm pleased to announce that we will showcase our BI-1206 rituximab data in Non-Hodgkin Lymphoma at ASH, and that will be during December 11 to 14. And then we also will present early data by mid-December this year for BI-1206 in combination with pembrolizumab in the Phase 1 trial in solid tumors.
We also have a poster on BT-001 preclinical data this time at SITC during November. And then I'm also very happy to tell you that we are on track for our CTA filing before year end for BI-1607, which is our second anti-FcGRIIB antibody.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |